emerging epidemic of nonalcoholic fatty liver diseaseimcourseonline.com/files/4 thursday/10 kathleen...
TRANSCRIPT
![Page 1: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/1.jpg)
Emerging Epidemic of Nonalcoholic Fatty Liver Disease
Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
![Page 2: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/2.jpg)
Outline Global Prevalence of NAFLD
NAFLD Diagnostics
Treatment of NASH
Predictors of Outcome in NAFLD
![Page 3: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/3.jpg)
What is NAFLD? • Chronic liver disease characterized by
excess storage of fat within the liver in the absence of significant alcohol use
• Type 2 Diabetes • Obesity • Dyslipidemia • Metabolic syndrome
• Obstructive sleep apnea
• Hypothyroidism • Polycystic ovary
syndrome
Major Comorbidities Emerging Associations
![Page 4: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/4.jpg)
Steatosis Steatohepatitis
Cirrhosis
Nonalcoholic Fatty liver Disease
![Page 5: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/5.jpg)
Fatty hepatocytes
Intracellular fat deposition
Steatosis
![Page 6: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/6.jpg)
Fibrosis Inflammation, ballooning Fat deposits
Nonalcoholic Steatohepatitis (NASH)
![Page 7: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/7.jpg)
Cirrhosis
Nodules surrounded by
fibrosis
![Page 8: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/8.jpg)
NAFLD Global Prevalence: 25%
Z. Younossi et, Hep 2016
NASH Prevalence: 1.5-6.6%
![Page 9: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/9.jpg)
NAFLD Prevalence Increases with Age
No difference in NAFLD prevalence by gender Slide Adapted and Courtesy of Z. Younossi Z. Younossi et, Hep 2016
![Page 10: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/10.jpg)
Prevalence of NAFLD in High Risk Populations
Prevalence by Ultrasound from NHANES III
Slide Adapted and Courtesy of Z. Younossi Z. Younossi et, Hep 2016 Z. Younossi et al. Medicine 2012
NAFLD not confined to high-risk populations Prevalence in lean: 7% Women Young age Normal ALT
![Page 11: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/11.jpg)
Screening for NAFLD: Area of Controversy
KE Corey et al. DDS 2016
Markov model comparing 2 management strategies for 50- year-olds with diabetes •No Screening strategy: no screening, although NASH may be incidentally dxd NASH Screening strategy: one-time screening ultrasound, + ultrasound → liver biopsy, + NASH → medical therapy (vitamin E) End-points 1) Life years, 2) QALYs gained, 3) costs, 4)incremental cost-effectiveness ratios (ICERs), 5) Progressive liver disease
Conclusion: No significant benefit to population based screening at this time
![Page 12: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/12.jpg)
Screening for NAFLD: Area of Controversy
• European Association for the Study of the Liver Guidelines (2017) – NAFLD screening in individuals with:
• Insulin resistance/Diabetes • Metabolic syndrome • Obesity
• American Association for the Study of Liver Disease Guidelines (2012) – Screening not recommended
![Page 13: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/13.jpg)
Testing for Incidentally Noted Steatosis
• Steatosis on imaging: – Evaluation warranted regardless of LFTs as
they are normal in 70-80% of NAFLD/NASH – Screen for metabolic syndrome (high risk for
NASH) – Screen for secondary causes of FLD including
alcohol, hepatitis C (gt 3), medications
![Page 14: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/14.jpg)
Testing for Incidentally Noted Abnormal LFTs
• NAFLD is most common cause of abnormal LFTs in US
• Evaluate for all causes of abnormal LFTs
• Ultrasound evaluation for steatosis
![Page 15: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/15.jpg)
Who Should Undergo Liver Biopsy?
• Patients with uncertain diagnosis – Ex. Steatosis on US but high titer ANA, ASMA
• Patients with evidence of chronic liver disease – Ex. Low platelets, evaluated INR
• Patients with high risk non-invasive scores – NAFLD Fibrosis Score (composite of
laboratory tests) – Elastrography
![Page 16: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/16.jpg)
![Page 17: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/17.jpg)
What Predicts Outcomes in NAFLD?
• 619 patients from US, Europe and Thailand with biopsy-proven NAFLD – 45.9% NASH/borderline NASH – 54.1% non-NAFLD
• Followed for median 12.6 years
• 33.2% died or underwent liver transplantation
P Angulo et al. Gastro 2016
![Page 18: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/18.jpg)
All Fibrosis Stages Predict Death/Liver Transplant
P Angulo et al. Gastro 2016
![Page 19: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/19.jpg)
Fibrosis Predicts Death and Liver Transplantation
Treatment should target those with fibrosis, diabetes, tobacco use. P Angulo et al. Gastro 2016
![Page 20: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/20.jpg)
Weight Loss is Foundation of NASH and Fibrosis Treatment • Prospective cohort of 293 adults with
biopsy-proven NASH in Havana, Cuba • Placed on low-fat, average protein diet
with focus on complex carbohydrates, fruits, vegetables
• Counseled to decrease caloric intake
E. Vilar-Gomez et al. Gastro 2016
![Page 21: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/21.jpg)
Weight Loss is Foundation of NASH and Fibrosis Treatment • Physical activity: started 90 minutes per
week, increase to 200 minutes per week
• Followed for 12 months
• Repeat biopsy at study completion
E. Vilar-Gomez et al. Gastro 2016
![Page 22: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/22.jpg)
Weight Loss Varied Among Subjects
70%
12% 8% 10%
0% 10% 20% 30% 40% 50% 60% 70% 80%
<5% 5-6.99% 7-9.99% >=10%
Percent Total Body Weight Loss in Vilar-Gomez Study
![Page 23: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/23.jpg)
Weight Loss Can Meaningfully Impact NASH
E. Vilar-Gomez et al. Gastro 2016
![Page 24: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/24.jpg)
Weight Loss Can Meaningfully Impact NASH
![Page 25: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/25.jpg)
Limitations • Only assessed impact of weight loss on
histology after12 months; no longer term follow-up of weight or histology
• Only 30% achieved >5% TBW
• Weight loss surgery is an effective alternative in appropriate patients
![Page 26: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/26.jpg)
Standard of Care NASH Treatment: Lifestyle
Treatment Dose Population Outcomes Weight loss via lifestyle intervention
7-10% total body weight loss
NASH with and without DM
Improvement in steatosis and inflammation
Weight loss via Surgery
Overweight F3-4 BMI>29, all F stages
Improves NASH and fibrosis in majority, increase LY and QALY
Mediterranean Diet
Radiographic NAFLD
Improvement in radiographic NAFLD, controlled for weight loss
Exercise ≥90 minutes weekly
Radiographic NAFLD
Improvement in radiographic steatosis, ALT level
Ekstedt et al., J of Hepatology 2007 , Mummadi et al., CGH 2008 . Pomrat et al., Hepatology 2010 , Taitano et al,. J Gastro Surg 2015, Musso et al. Hepatology 2010, LB Van Wagner Ann Hep 2011, Ryan et al. J Hep 2013, Vilar-Gomez et al., Gastro 2016, Klebanoff et al. Hepatology 2017
![Page 27: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/27.jpg)
Standard of Care NASH Treatment: Medications
Treatment Dose Population Outcomes Vitamin E 800 units daily NASH without DM Improvement in
steatosis and inflammation
Pioglitazone 30-45 mg daily NASH with DM Improvement in steatosis and inflammation
Ekstedt et al., J of Hep 2007
Mummadi et al., CGH 2008
Pomrat et al., Hep 2010
Taitano et al,. J Gastro Surg 2015 Musso et al. Hep 2010 LB Van Wagner Ann Hep 2011
![Page 28: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/28.jpg)
Vitamin E for NASH: PIVENS Trial
A. Sanyal et al., NEJM 2010
![Page 29: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/29.jpg)
Vitamin E for NASH: PIVENS Trial
A. Sanyal et al., NEJM 2010
Placebo VitE Pio Vit E vs Placebo
Pio vs. Placebo
Primary Outcome, %
19%
43%
34%
0.001
0.04
NASH resolution,%
21%
36%
47%
0.05
0.001
Fibrosis Improvement, %
31%
41%
44%
0.24
0.12
![Page 30: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/30.jpg)
Vitamin E and NASH • Prostate CA: Avoid VitE in individuals with
personal or family history of prostate CA • Mortality: Discuss risk of all-cause mortality
with patients and weight risks and benefits • Use: Vitamin E recommended for use in biopsy-
proven NASH in non-diabetics
![Page 31: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/31.jpg)
• Aim: Evaluate impact pio on NASH
• Intervention: Pio 45mg or placebo for 18 months; all received counseling on hypocaloric diet
• Population: 101 Adults with pre-DM or DM, with biopsy-proven NASH
K Cusi et al., Ann Int Med 2016
![Page 32: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/32.jpg)
In Diabetes and Pre-DM, Pio Improved NASH
K Cusi et al., Ann Int Med 2016
![Page 33: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/33.jpg)
Pio Leads to Weight Gain
K Cusi et al., Ann Int Med 2016
• Pio group gained significantly more weight than placebo (+2.5kg, 95% CI 0.4-4.5, P=0.02)
• Less than seen in pio group in PIVENS (mean 4.7 kg), maybe due to dietary counseling
• Pio had positive impact on lipids – HDL (44mg/dL vs 40mg/dL, P<0.001) – Triglycerides (127mg/dL vs 144mg/dL, P=0.018)
![Page 34: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/34.jpg)
Pioglitazone and Adverse Effects
• CHF: For CHF, careful monitoring for CHF and rapid discontinued for symptoms recommended
• Bladder CA: Do not prescribe in those with bladder cancer and with caution in those with history of bladder cancer
• Weight gain: Requires dietary couseling • Use: Biopsy-proven NASH in those with
diabetes
RW Nesto et al., Circ 2003 AM Lincoff et al., JAMA 2007 JA Dormandy et al., Lancet 2005
![Page 35: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/35.jpg)
Pharmacotherapy in Development Treatment MOA Population Outcomes Current Trial Ongoing Phase 3 Trials Genfit/Elafibranor (GFT-505), 120mg PO daily
Dual PPAR alph/delta activator
NAS≥3 Phase 2b GOLDEN-505 In NAS>4, resolution of NASH & in responders, reduction in fibrosis No benefit in NAS<4
RESOLVE-IT NASH and NAS>=4, F1-3 72 weeks PE: 1) NASH resolution w/o worsening fibrosis, 2) mortality, cirrhosis, LRO
OCA 25mg po daily
Farnesoid receptor X ligand/agonist
Non-cirrhotic NASH, 50% DM
Phase 2 FLINT: NAS improvement in 46% vs. 21% placebo, Fibrosis≥1 35% vs.19%
REGENERATE NASH and fibrosis 72 weeks PE: 1) Fibrosis improvement, no worsening NASH, 2) NASH resolution
Ongoing Phase 2 Trials
Conatus/Emricasan
Pan-caspase inhibitor, oral High first pass metabolism
Different etiologies of cirrhosis including 23% NASH
Reduction in caspase-cleaved CK18 Improvement in MELD, TB, INR, in those with MELD>15
ENCORE-NF trial 72W NASH + fibrosis (no cirrhosis) PE: reduction in fibrosis
Galectin/GR-MD-02 Galectin-3 protein binds to terminal galactose residues on glycoproteins, inhibits galectin in macrophages
NASH with fibrosis Decreased markers of fibrosis
NASH-CX trial NASH cirrhosis PE: HVPG NASH-FX Trial NASH + AF PE: MRE
![Page 36: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/36.jpg)
Pharmacotherapy in Development Treatment MOA Population Outcomes Current Trial Ongoing Phase 2 Continued
Cenicriviroc oral
Immunomodulator blocks 2 chemokine receptors, CCR2, CCR5 on monocytes, lymphocytes, HSC, Kupffer cells; developed as HIV drug
HIV Improved APRI and FIB-4 ORION 24 weeks in suspected NAFLD, IR, obesoty PE: Imaging, IS, LFTs CENTAUR 2 year NASH + fibrosis (no cirrhosis) PE: histology
Galmed/Aramchol
Conjugate of cholic acid and arachidic acid, first-in-class member of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs)
NASH Reduced liver fat in dose dependent manner 100mg 2.89%, 300mg 12.57%, improved HOMA
Victoza/Liraglutide GLP-1 analog, improves IS, FAO, hepatic glucose metabolis; decrease lipogenesis
NASH and DM
NASH resolution: LGT 39% vs. placebo 9%
Simtuzumab (LOXL-2 inhibitor)
inhibitory monoclonal antibody against L2 type of lysyl oxidase (LOX), enzyme family that stabilizes ECM
NASH Improved ALT and AST NASH cirrhosis PE: HVPG, liver-related events/mortality NASH+ Advanced fibrosis PE: Hepatic collagen
![Page 37: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/37.jpg)
Pharmacotherapy in Development Treatment MOA Population Outcomes Current Trial Ongoing Phase 2 Continued
GS-4997 Inhibits Apoptosis signal-regulating kinase 1 (ASK1): MAP3 kinase, activates p38/JNK pathway, causes apoptosis and fibrosis Contributes to IR
Murine models Decreases diet-induced steatosis and fibrosis
Open label, 24 week study GS-4997 +/- simtuzumab in NASH with F2-3
Amlexanox IkB kinase inhibitor Animal models Decreases steatosis, hepatic inflammatory gene expression
12 weeks in DM, fatty liver on imaging PE: Hepatic fat, A1C, weight
PXS-4728A Selective irreversible VAP-1 inhibitor VAP1 supports liver recruitment of lymps, ROS generation
Murine model (STZ/HFD) Improved NASH histology Phase 1 recently completed
IMM-124E IgG rich extract of bovine colostrum from cows immunized against LPS
10 patients, bx-proven NASH
30 days improved IS and glycemia
Phase 2 evaluating impact on MR fat in progress
Solithromycin Macrolide antibiotic Murine model Decreased ballooning and inflammation
Phase 2 open label for 13 weeks rx on non-cirrhotic NASH PE: Histology
![Page 38: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/38.jpg)
Conclusions • NAFLD has a 25% prevalence globally • Fibrosis most important predictor death/LTx • Weight loss is the foundation of therapy • For biopsy-proven NASH with Fibrosis
– Vitamin E 800U daily without diabetes – Pioglitazone 30-45mg with diabetes – Consider weight loss surgery
• Discuss adverse events
![Page 39: Emerging Epidemic of Nonalcoholic Fatty Liver Diseaseimcourseonline.com/files/4 Thursday/10 Kathleen Corey non-alcoholi… · Emerging Epidemic of Nonalcoholic Fatty Liver Disease](https://reader031.vdocuments.us/reader031/viewer/2022011913/5fb5b04e9ea5c142646c4624/html5/thumbnails/39.jpg)
Thank you